B cell

Hence CLL appears to be a B-cell malignancy triggered or facilitated in its development and evolution by an auto-Ag.

B cell activating factor (BAFF) is one of the TNF family member, regulates the survival and maturation of B lymphocyte.

Polymerase chain reaction did not show B cell or T cell rearrangement.

They were working on a type of cancer known as follicular B-cell lymphoma, a kind of non-Hodgkin's lymphoma that attacks the immune system.

Multiple myeloma (MM) is an incurable clonal B-cell malignancy with terminally differentiated plasma cells.

Hashimoto's thyroiditis results from abnormal T cell activation and subsequent B cell stimulation to secrete a variety of autoantibodies.

The humoral immune response to the main NDV, the identification of B-cell epitopes revealed ND is the essence of humoral immunity.

abstract: Objective Establishment of human B cell line expressing specific immunoglobulin variable regions antigen.

PAX5 is a member of the PAX family of developmental transcription factors with an important role in B-cell development.

Results: B cell deficiency significantly delayed diabetes development in chronically inflamed islets.

Conclusion: The mechanism of glucose-decreasing effect of the FMH is to possibly recover the destroyed B cell in the islet.

It usually occurs on the base of the lymphoma B-cell clone as a result of the persistent infection of Helicobactor Pylori.

Histopathology examination of transplanted tumors showed primary lymphoma of the liver(non-Hodgkin's, B cell).

Rituximab, an antibody recognizing the CD20 B cell antigen, has proven to be of especially high clinical importance.

The process of the immune responses are executed by the cell immunity and humoral immunity induced by the T cell and B cell respectively.

The treatment options for this group of patients are described in the NCCN Treatment Summary for diffuse large B-cell lymphoma.

The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules.

Whether gene-expression signatures correlate with survival after treatment of diffuse large-B-cell lymphoma is unclear.

Objective To evaluate the efficacy and toxicity of combination of Rituximab and CHOP regimen in diffuse large B-cell lymphoma(DLBCL).

Work done previously by Professor Mackay on BAFF showed that levels correlate with B cell hyperplasia (expansion) and cancer.

All tumors are the diffuse NHL, including mainly large cell lymphomas and immunophenotypic features of B-cell lymphomas.

Activated T cells release a number of lymph toxins, interferon, and B cell growth and activation factors.

Therefore, each initially stimulated B cell produces a clone of plasma cells, all producing the same specific antibody.

Central tolerance is immunological tolerance developed during T and B cell differentiation.

Indeed one of the things that is most effective in preventing T cell help for a B cell response is blocking B-7 co-stimulation.

Objective: To improve the understanding of primary diffuse large B-cell lymphoma of the breast.

Asymptomatic persons with fewer CLL-phenotype cells have monoclonal B-cell lymphocytosis (MBL).

Research Design and Methods: RIP-TNF-NOD mice were crossed to B cell deficient NOD mice and diabetes development monitored.

Immunohistochemical analysis confirmed that all the cases were B-cell lymphoma.

They have traditionally been viewed mainly as short-lived end-stage products of B-cell differentiation that deserve little interest.

B cell activated co-receptor plays important roles in linkage of innate and acquired humoral immune responses.

The expression of B cell markers and major histocompatibility complex (MHC) on cell surface were detected by FCM.

B-cell CLL constitutes one fourth of all leukemias but less than 5% of adult leukemias in Asian populations.

In HIV [research], we are looking at tonnes of data for T cell responses, B cell responses, tonnes of genetic data.

It is one of the most common types of extranodular low-grade B cell lymphoma.

Preferably, investigative immunohistochemistry of this case should include two T cell markers, two B cell markers, CD30, EMA and ALK -1.

Instead at the CTL transition stage, B cell deficiency resulted in apoptosis of intra-islet CTL.

This study was to investigate the efficacy and safety of rituximab-containing regimens for patients with indolent B-cell lymphoma in China.

The spleen is frequently involved in B-cell lymphomas other than splenic marginal zone lymphoma.

In the paper, the several efficient methods in research of B-cell epitope were summarized and discussed.

"Distinct Types of Diffuse Large B Cell Lymphoma Identified by Gene Expression Profiling. " Nature (2000).

RESULTSShangyangyu ointment can increase the cell hyperplasia and Induce the proliferation of B cell and T cell lymphocyte.

Their expression in B-cell lymphoma reflected the anti-tumor immunologic reaction of host.

"We're using rubber bands and bubbles to show the B cell alerting the T cell that there's a foreign invader, " Ms. Batkin said.

Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous disease.

Can you talk about the possibilities of strategies for B cell-directed therapy for the induction of transplant tolerance?

Students assumed the roles of the antigen, B cell, T cell and antibodies.

Objective To explore the level of B cell and its CD40 in the patients with idiopathic thrombocytopenic purpura(ITP).

T-cell help for B cells is essential for high-affinity antibody responses and B-cell memory.

Conclusion Most cases were B-cell type lymphoma with low-grade malignancy.

membrane immunoglobulin is the B cell antigen receptor.

Objective To investigate the mechanism of cytotoxic efficacy of CD4 T cells in B cell non-Hodgkin s lymphoma(NHL) .

The therapy focused on CD22, neither affects its expression in tissue nor inhibits cytopoiesis of B cell.

Aim To explore the expression of CD44 molecule in non-Hodgkin's lymphoma (NHL) and the difference between T cell and B cell NHL.

Rituximab is a chimeric monoclonal antibody that targets the CD20 molecule on the B-cell surface.

Results All the 11cases were B-cell type lymphoma, and male patients were more common.

Based on the clinicopathological and immunohistochemical findings, a diagnosis of primary cutaneous diffuse large B-cell lymphoma was made.

Diffuse large B cell lymphoma was proved.

Methods 6 elderly patients with B-cell Non-Hodgkin's Lymphoma were treated with Rituximab combined with CTNP regiment in our department.

Multiple myeloma is a kind of malignant hyperplastic diseases, which is origined from B cell line and can produce monoclonal immunoglobulin.

The CD20 cell marker appears early in the process of B cell development.

Results There were 7 cases of follicular lymphoma, 2 cases of lympho-plasmacytic lymphoma and 2 cases of diffuse large B-cell lymphoma.

A study of rituximab combined with DICE regimen for treatment of the relapsed or refractory aggressive B-cell Lymphoma

A case of marginal zone B-cell lymphoma of the pulmonary mucosa-associated lymphoid tissue type

The pathological characteristics and dissemination mechanism of primary B cell lymphoma of the gastrointestinal tract

Objective To study the association of Epstein-Barr virus with B cell lymphomas in immunocompetent patients.

Morphologic and immunohistochemical study of small B-cell lymphomas

Splenic marginal zone B-cell lymphoma of a clinicopathological and immunohistochemical study

Study on Detection of Clonal Immunoglobulin Heavy Chain Gene Rearrangement in Paraffin-embedded Tissues from B-cell Lymphomas

Evaluation of rituximab on purgation and mobilization of peripheral blood stem cells in patients with B-cell non-Hodgkin lymphoma

Clinical Analysis of Rituximab Combined with Chemotherapy in Treating Aggressive B-Cell Non-Hodgkin's Lymphoma

The Experimental Study on Idiotypic DNA Vaccine against Human B-cell Lymphoma to Induce Antitumor Immune Response

Morphologic study of tonsillar B-cell lymphomas

Efficacy of Rituximab-containing Salvage Regimens on Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Marginal zone B-cell lymphoma: Clinical features and molecular cytogenetic changes

Prognostic value of minimal residual disease in childhood B-cell acute lymphoblastic leukemia

Short-term efficacy of combination of MabThera and CEOP regimen in the treatment of aggressive B-cell lymphoma

Lymphoid infiltrates in B cell non Hodgkin' s lymphoma: comparing nuclear characteristics between lymph node and bone marrow;

Clinical and Survival Analysis of Primary Intestinal Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Prediction of the Secondary Structure and B-Cell Epitope of Human Mast Cell Chymase

hepatitis B; cell cultivation; dendritic cells;

Efficacy of Rituximab-containing Regimens on Indolent B-cell Lymphoma--a Report of 34 Cases

Role of hepatitis virus infection in pathogenesis of B-cell non-Hodgkin's lymphoma

Recent progress in molecular pathogenesis of B-cell lymphoma

EBV positive diffuse large B cell lymphoma of the elderly

b cell depletion in treating rheumatoid arthritis

Expression and significance of cyclin A and PCNA in B-cell non-Hodgkin's lymphoma

Progress of treatment of primary cutaneous B-cell lymphoma

Identifying Prognosis Factors Related to Primary Gastric B-Cell Lymphoma

Lymph node marginal zone B-cell lymphoma: A clinicopathological analysis

Lymph node marginal zone B-cell lymphoma: A clinicopathological analysis

Clinical advances in the treatment of B-cell lymphoma by rituximab

Study of mutations in 5'-noncoding region of BCL-6 gene in B-cell non-Hodgkin's lymphomas

Recent Progresses on B-cell Activating Factor

Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue lymphoma, MALTL

Marginal zone B-cell lymphoma of the MALT type

primary diffuse large B cell lymphoma of CNS, CNS DLBCL

Molecular Biology of B-Cell and T-Cell Development

Expression and Clinical Significance of MCL-1 in B-Cell Non-HodgKin's Lymphoma

Studies on the B-Cell Epitopes of L-asparaginase

Studies on the B-Cell Epitopes of L-asparaginase

intravascular large B cell lymphoma, IVLBCL

B-cell diffuse large cell lymphoma, B-DLCL

A quantitative morphological study on one patient's mediastinal primary large B cell

Microsatellite instability and loss of heterozygosity at chromosome 6 in B-cell lymphoma